Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
70.41
-1.40 (-1.95%)
At close: Mar 28, 2025, 4:00 PM
71.41
+1.00 (1.42%)
After-hours: Mar 28, 2025, 6:49 PM EDT

Company Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene.

The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F.

Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon.

The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics, Inc.
Sarepta Therapeutics logo
Country United States
Founded 1980
IPO Date Jun 3, 1997
Industry Biotechnology
Sector Healthcare
Employees 1,372
CEO Douglas Ingram

Contact Details

Address:
215 First Street, Suite 415
Cambridge, Massachusetts 02142
United States
Phone 617 274 4000
Website sarepta.com

Stock Details

Ticker Symbol SRPT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000873303
CUSIP Number 803607100
ISIN Number US8036071004
Employer ID 93-0797222
SIC Code 2834

Key Executives

Name Position
Douglas S. Ingram Esq. President, Chief Executive Officer and Director
Ian Michael Estepan Executive Vice President and Chief Financial Officer
Bilal Arif Executive Vice President and Chief Technical Operations Officer
Dr. Louise R. Rodino-Klapac Ph.D. Executive Vice President, Chief Scientific Officer and Head of Research and Development
Francesca T. Nolan Executive Director of Investor Relations and Corporate Communications
Cristin L. Rothfuss J.D. Executive Vice President and Chief General Counsel
Alison Nasisi Executive Vice President and Chief People Officer
Dr. Diane L. Berry Ph.D. Executive Vice President and Chief of Global Policy and Advocacy Officer
Dallan Murray Executive Vice President and Chief Customer Officer
Joseph Bratica Controller and Vice President

Latest SEC Filings

Date Type Title
Mar 12, 2025 144 Filing
Mar 3, 2025 S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 28, 2025 10-K Annual Report
Feb 26, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 14, 2025 8-K Current Report
Jan 13, 2025 8-K Current Report
Dec 12, 2024 144 Filing
Dec 5, 2024 144 Filing
Nov 26, 2024 8-K Current Report